Immucell (ICCC) Receivables (2010 - 2026)
Immucell's (ICCC) quarterly Receivables came in at $3.5 million in Q4 2025, up 3623.81% YoY from $92652.0 in Q4 2024, and up 32.24% on a QoQ basis from $2.6 million in Q3 2025.
Immucell (ICCC) Receivables (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Receivables data on file, last reported at $3.5 million in Q4 2025.
- Quarterly Receivables rose 3623.81% year-over-year to $3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.5 million (up 3623.81% YoY) and the FY2025 annual result came in at $3.5 million, down 9.48% from the prior year.
- Receivables improved to $3.5 million in Q4 2025, from $2.6 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $3.5 million in Q4 2025 to a low of $92652.0 in Q4 2024.
- A 5-year average of $2.2 million and a median of $2.3 million in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2024 — Receivables sank 95.84% — and 2025, when it soared 3623.81%.
- Tracing ICCC's Receivables over 5 years: stood at $2.7 million in 2021, then sank by 34.36% to $1.8 million in 2022, then rose by 23.27% to $2.2 million in 2023, then slumped by 95.84% to $92652.0 in 2024, then soared by 3623.81% to $3.5 million in 2025.
- The last three Receivables figures came in at $3.5 million (Q4 2025), $2.6 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | - |
| 10 | Immucell | 91.37 Mn | 82.51 Mn | 2.44 Mn | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.90 Mn |
| Dec 31, 2025 | 3.45 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | 2.42 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Dec 31, 2024 | 92,652.00 |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 1.97 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 2.11 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 2.14 Mn |
| Dec 31, 2022 | 1.81 Mn |
| Sep 30, 2022 | 1.74 Mn |
| Jun 30, 2022 | 1.44 Mn |
| Mar 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.75 Mn |
| Sep 30, 2021 | 2.44 Mn |
| Jun 30, 2021 | 2.16 Mn |